Contributions
Abstract: EP1769
Type: ePoster
Abstract Category: Therapy - disease modifying - 30 Tools for detecting therapeutic response
Background: Patient reported outcome measures (PROMs) has been included in recent trials involving both disease modifying and symptom management drugs in multiple sclerosis (MS). There is lack of information on PROMs outside the trial setting in patients treated with different disease modifying treatments (DMT).
Methods: All patients with Relapsing remitting MS (RRMS) treated with DMT's including newly licenced drugs prospectively completed Leeds Multiple sclerosis Quality of life (LMSQoL) scale and United Kingdom Neurological Disability scale (UKNDS) on an annual basis. Expanded Disability Severity Score (EDSS) was also assessed during these visits. LMSQoL is an eight item scale with resulting scores from 8 to 32, with higher scores reflecting higher levels of well-being. UKNDS has 12 functional domains with an overall score ranging between 0 (no disability) to 60 (maximum possible disability). Mean scores for LMSQoL, UKNDS during their first 12 months and 24 months were compared to pre-treatment baseline along with the median EDSS.
Results: In total we analysed PROMs from 962 patients. There were 595 patients on injectable (Beta-interferon and Glatiramer acetate) treatments, 92 on Natalizumab, 109 on Fingolimod, 151 on Dimethyl fumarate, 7 on Alemtuzumab and 8 on Teriflunomide.
In the injectable group there was 2 point increase (p-0.0001) in LMSQol with small decrease in the mean UKNDS which is not statistically significant with median EDSS remaining stable at 2. In Natalizumab group there was increase of 3.36 points (p-0.0001) on LMSQoL and decrease of 4.89 points (p-0.001) on UKNDS with unchanged median EDSS. In Alemtuzumab group there was 5.81 point increase from baseline (p - 0.07) in LMSQoL, 16.38 decreased from baseline (p-0.007) in UKNDS with 1.5 point reduction in median EDSS. There was no statistically significant change in PROMs in the rest of the treatment groups over the observed 24 month period.
Conclusion: There was improvement in the well-being scores from the baseline in people who are on Natalizumab and Injectable treatments. Natalizumab and Alemtuzumab group also reported improvement in their disability.
Disclosure:
Maruthi Vinjam: Has received support to attend educational meetings from Merck, Biogen, Novartis, and Genzyme
Melanie Russell: nothing to disclose
Oliver Lily: Has received support to attend educational meetings from Biogen and Teva
Helen L Ford: In the last year HLF has received consultancy/speaker fees and support to attend educational meetings from Merck, Novartis, Teva and Genzyme
Abstract: EP1769
Type: ePoster
Abstract Category: Therapy - disease modifying - 30 Tools for detecting therapeutic response
Background: Patient reported outcome measures (PROMs) has been included in recent trials involving both disease modifying and symptom management drugs in multiple sclerosis (MS). There is lack of information on PROMs outside the trial setting in patients treated with different disease modifying treatments (DMT).
Methods: All patients with Relapsing remitting MS (RRMS) treated with DMT's including newly licenced drugs prospectively completed Leeds Multiple sclerosis Quality of life (LMSQoL) scale and United Kingdom Neurological Disability scale (UKNDS) on an annual basis. Expanded Disability Severity Score (EDSS) was also assessed during these visits. LMSQoL is an eight item scale with resulting scores from 8 to 32, with higher scores reflecting higher levels of well-being. UKNDS has 12 functional domains with an overall score ranging between 0 (no disability) to 60 (maximum possible disability). Mean scores for LMSQoL, UKNDS during their first 12 months and 24 months were compared to pre-treatment baseline along with the median EDSS.
Results: In total we analysed PROMs from 962 patients. There were 595 patients on injectable (Beta-interferon and Glatiramer acetate) treatments, 92 on Natalizumab, 109 on Fingolimod, 151 on Dimethyl fumarate, 7 on Alemtuzumab and 8 on Teriflunomide.
In the injectable group there was 2 point increase (p-0.0001) in LMSQol with small decrease in the mean UKNDS which is not statistically significant with median EDSS remaining stable at 2. In Natalizumab group there was increase of 3.36 points (p-0.0001) on LMSQoL and decrease of 4.89 points (p-0.001) on UKNDS with unchanged median EDSS. In Alemtuzumab group there was 5.81 point increase from baseline (p - 0.07) in LMSQoL, 16.38 decreased from baseline (p-0.007) in UKNDS with 1.5 point reduction in median EDSS. There was no statistically significant change in PROMs in the rest of the treatment groups over the observed 24 month period.
Conclusion: There was improvement in the well-being scores from the baseline in people who are on Natalizumab and Injectable treatments. Natalizumab and Alemtuzumab group also reported improvement in their disability.
Disclosure:
Maruthi Vinjam: Has received support to attend educational meetings from Merck, Biogen, Novartis, and Genzyme
Melanie Russell: nothing to disclose
Oliver Lily: Has received support to attend educational meetings from Biogen and Teva
Helen L Ford: In the last year HLF has received consultancy/speaker fees and support to attend educational meetings from Merck, Novartis, Teva and Genzyme